The findings could explain why the effects of psychedelics, such as neuroplasticity and even antidepressant action, vary between different drugs.
From July 1, psychiatrists in Australia will be allowed to prescribe MDMA and psilocybin as treatments for certain mental health conditions.
A single, moderate dose of psilocybin combined with psychological support counseling can rapidly and significantly reduce symptoms of depression, a new study has found.
Technology Networks – Analytical Cannabis’ sister publication – spoke to the team at Delix Therapeutics' to learn how their drugs can keep the benefits of psychedelics compounds while leaving behind the trip.
The credibility watchdog praised Analytical Cannabis’ dedication to fact-based reporting of cannabis industry events and relevant scientific research.
While these psychedelics users did tend to report an increased belief in the paranormal after their trip, superstitious beliefs largely remained unchained.
Analytical Cannabis rounds up the year’s top cannabis stories, with a particular focus on research and testing.
The first-of-its-kind phase 3 trial will soon begin in the UK to test whether ketamine can help treat patients with alcohol use disorder.
Dr. Perkins spoke with Technology Networks – the sister publication of Analytical Cannabis – to provide context on the latest research study and the next steps for the research group.